GYT HealthCare Services secures nearly ￥100M Series D to lead upgrade in primary blood purification sector

GYT HealthCare Services recently completed a Series D financing round of nearly 100 million yuan. This round was exclusively led by Zhesheng Xietong Life Health Fund (浙生协同生命健康基金). The raised capital will be primarily allocated to developing the company's core pipeline products, commercial expansion, and the construction of new production lines.

Since its establishment in 2016, GYT HealthCare Services has consistently focused on the blood purification product and technology service sector, dedicated to providing hospitals and nephrology patients with an integrated "equipment + consumables + chronic disease management + medical services" solution. The company's products and services have now covered over a thousand medical institutions, with the proportion of primary care institutions steadily increasing year by year. This growth fully demonstrates GYT's leading position in China's primary dialysis center market, aligning precisely with the tiered healthcare policy direction and effectively addressing pain points in primary dialysis centers related to professional capabilities, operational efficiency, and talent shortages.

As China's blood purification market enters a period of rapid growth and the domestic substitution process accelerates, GYT is comprehensively transitioning from a "medical product provider" to a "medical industrial system builder." Through a dual approach of industrial chain integration, mergers and acquisitions, and in-house product development, the company is building a deeply integrated "industry-academia-research" ecosystem for blood purification. With reliable industrial capacity and stable, high-quality products, GYT continues to strengthen its support for primary care, contributing professional expertise to promote balanced development of China's healthcare system and support the "Healthy China" national strategy.

GYT HealthCare Services has established a closed-loop development model of "service empowering industrial innovation, and industry empowering service quality enhancement." This approach has enabled the company to build a comprehensive blood purification product portfolio, including water treatment systems for hemodialysis, centralized liquid supply equipment, dialysis concentrates and powders, and dialyzers.

The company continuously drives technological breakthroughs, having innovatively developed a peritonitis prediction system (granted invention patents in the United States, EU, and China), mid-cut-off and high-cut-off dialyzers, peritoneal dialysis solutions, CRRT devices and related consumables, among other critical products. Simultaneously, GYT actively pursues merger and acquisition opportunities within the blood purification industry to accelerate the achievement of full-category coverage, end-to-end extension, and intelligent upgrading of its blood purification product system.